Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7453154 | 1.00 | MEN1 (0.47) | MEN1KMT2ACASP1SMN1; SMN2PLAU | |
| SCHEMBL3004207 | 0.83 | ALDH1A1 (0.48) | MEN1KMT2ACTSSNPC1RAB9A | |
| SCHEMBL6375660 | 0.83 | ALDH1A1 (0.48) | MEN1KMT2ACTSSNPC1RAB9A | |
| SCHEMBL1748476 | 0.83 | ALDH1A1 (0.48) | MEN1KMT2ACTSSNPC1RAB9A | |
| SCHEMBL8889711 | 0.83 | MEN1 (0.50) | MEN1KMT2ASMN1; SMN2CTSSNPC1 | |
| SCHEMBL27536278 | 0.82 | MEN1 (0.48) | MEN1KMT2ACASP1SMN1; SMN2PLAU | |
| SCHEMBL3537093 | 0.80 | EPHX2 (0.45) | KMT2A | |
| SCHEMBL28668556 | 0.80 | EPHX2 (0.45) | KMT2A | |
| SCHEMBL28546281 | 0.79 | KDM4E (0.45) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL6154376 | 0.79 | MEN1 (0.55) | MEN1KMT2ASMN1; SMN2CTSSNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0950046-B1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | NAEJA PHARMACEUTICAL INC (CA) | 2002-04-10 | — | — | EP | claimed |
| EP-0950046-A1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | SYNPHAR LABORATORIES INC. (CA) | 1999-10-20 | — | — | EP | claimed |
| US-5959123-A | REACATING SUBSTITUTED AMINO ACID WITH 3-AMINO-4-SUBSTITUTED-AZETIDINE-2-ONE COMPOUND TO FORM 3, 4-DISUBSTITUTED-AZETIDINE-2-ONE COMPOUND; USEFUL FOR TREATING MUSCULAR DYSTROPHY, ARTHRITIS, VIRAL AND PARASITIC INFECTIONS | SYNPHAR LABORATORIES, INC. (CA) | 1999-09-28 | — | — | US | claimed |
| WO-1998012176-A1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | SYNPHAR LABORATORIES INC. (US) | 1998-03-26 | — | — | WO | claimed |
| EP-2014291-B1 | Piperazinone compounds as anti-tumor and anti-cancer agents | UNIV YALE (US) | 2011-10-26 | — | — | EP | disclosed |
| US-7763620-B2 | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment | YALE UNIVERSITY (US) | 2010-07-27 | — | — | US | disclosed |
| EP-1427418-B1 | PIPERAZINONE COMPOUNDS AS ANTI-TUMOR AND ANTI-CANCER AGENTS | UNIV YALE (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-2014291-A2 | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment | YALE UNIVERSITY (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20080221123-A1 | Piperazinone Compounds as Anti-Tumor and Anti-Cancer Agents and Methods of Treatment | YALE UNIVERSITY | 2008-09-11 | — | — | US | disclosed |
| EP-0950046-B1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | NAEJA PHARMACEUTICAL INC (CA) | 2002-04-10 | — | — | EP | disclosed |
| EP-0950046-A1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | SYNPHAR LABORATORIES INC. (CA) | 1999-10-20 | — | — | EP | disclosed |
| US-5959123-A | REACATING SUBSTITUTED AMINO ACID WITH 3-AMINO-4-SUBSTITUTED-AZETIDINE-2-ONE COMPOUND TO FORM 3, 4-DISUBSTITUTED-AZETIDINE-2-ONE COMPOUND; USEFUL FOR TREATING MUSCULAR DYSTROPHY, ARTHRITIS, VIRAL AND PARASITIC INFECTIONS | SYNPHAR LABORATORIES, INC. (CA) | 1999-09-28 | — | — | US | disclosed |
| WO-1998012176-A1 | 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS | SYNPHAR LABORATORIES INC. (US) | 1998-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221123-A1 | Piperazinone Compounds as Anti-Tumor and Anti-Cancer Agents and Methods of Treatment | EP300, HDAC5, VHL | MEN1 2749/4885KMT2A 1903/4885CASP1 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.